JonesTrading analyst Prakhar Agrawal maintained a Buy rating on Arena Pharmaceuticals on Wednesday, setting a price target of $94, which is approximately 34.88% above the present...
The FDA has granted Orphan Drug Designation status to Arena Pharmaceuticals' (ARNA) etrasimod, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the...
Broader markets are close to record highs. Year-to-date, the Dow Jones Industrial Average, the S&P 500 and the NASDAQ 100 are up around 11.5%, 11.6% and 8.2%,...
1. Arena PharmaceuticalsArena Pharmaceuticals (NASDAQ:ARNA) broke out, and I put a swing on it on Tuesday. I like the look when it broke through resistance, and then it kept...
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn’s disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.